Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada’s experience with the live-attenuated influenza vaccine

Linlu Zhao1*, Kelsey Young1, Althea House1, Rob Stirling1, Matthew Tunis1

Abstract

Over the last several years, the recommended use of the live-attenuated influenza vaccine (LAIV) for children has evolved in the United States (US) in response to evidence of a potential decrease in LAIV effectiveness based on post-market monitoring. These issues were not observed in Canada or elsewhere; consequently, recommendations from Canada’s National Advisory Committee on Immunization (NACI) and the US Advisory Committee on Immunization Practices (ACIP) on whether to use LAIV differed for two influenza seasons (2016–2017 and 2017–2018).

This retrospective describes how NACI arrived at its recommendations in response to post-market signals of reduced LAIV performance from the US in 2013–2014 and again in 2015–2016. NACI’s experience with LAIV marks the first time in Canada where a preferential recommendation on the use of an influenza vaccine in a routine immunization program was reversed. This experience highlights the importance of ongoing post-market monitoring of vaccines, international collaboration and careful consideration of local context to inform vaccine recommendations. NACI’s capacity for timely responses to post-market vaccine performance signals will facilitate responsiveness to similar post-market monitoring signals from the coronavirus disease 2019 (COVID-19) vaccines.

Introduction

The World Health Organization recommends that every country have a National Immunization Technical Advisory Group (NITAG) of experts to provide independent, evidence-informed vaccine recommendations (1,2). Canada’s National Advisory Committee on Immunization (NACI), an external advisory body to the Public Health Agency of Canada (PHAC), is one of the longest standing NITAGs in the world. NACI has been providing ongoing and timely expert and evidence-based advice on the use of vaccines to protect Canadians for over 50 years.

NACI’s recommendations are developed using an evidence-based process, which broadly involves the sequential stages of evidence gathering, synthesis and translation to recommendations (3). Triggers for NACI guidance development include—but are not limited to—authorization of new vaccines in the Canadian market; changes to indications for vaccine use; detection of vaccine safety or performance signals through post-market monitoring; the publication of pivotal new research; specific concerns raised by provincial and territorial immunization programs; and significant changes in international guidance.
Findings of suboptimal effectiveness of live-attenuated influenza vaccine (LAIV) in the United States (US) in 2014 and again in 2016 were triggers for NACI to review and deliberate on their guidance on the use of the LAIV in Canada.

This article documents NACI’s responses to these signals of potentially decreased LAIV effectiveness in the US and highlights the importance of ongoing post-market monitoring of vaccines.

Triggers and responses

LAIV has been demonstrated to be safe and efficacious through clinical trials, but real-world evidence collected after LAIV was made available for use showed that it may be less effective in some contexts than the more established inactivated influenza vaccines (IIVs).

LAIV was first marketed in Canada as a trivalent formulation for individuals aged 2–59 years in June 2010, seven years after the vaccine was first marketed in the US. It was offered in various provinces and territories as part of publicly funded immunization programs beginning in 2012–2013. The trivalent formulation of LAIV was replaced with the quadrivalent formulation in Canada starting in the 2014–2015 influenza season.

In 2011, NACI made a preferential recommendation for the use of trivalent LAIV over trivalent IIV for children and adolescents aged 2–17 years for the 2011–2012 season (quadrivalent IIV for children and adolescents aged 2–17 years for the 2011–2012 season; this evidence was presented to ACIP (6)).

This decision was based upon favourable efficacy data from clinical trials and post-market safety data, with acknowledgement of stronger evidence for superior efficacy in younger children (younger than six years old) than for older children. Based on the efficacy data, in June 2014 the Advisory Committee on Immunization Practices (ACIP)—the US counterpart to NACI—recommended the preferential use of quadrivalent LAIV over trivalent or quadrivalent IIV for the 2014–2015 season for children 2–8 years old. The upper age limit of ACIP’s recommendation was chosen based on programmatic consistency (i.e. in the US, eight years of age is also the upper age limit for the receipt of two doses of influenza vaccine in a previously unvaccinated child) (5). These preferential LAIV use recommendations by NACI and ACIP were in place when findings of reduced LAIV effectiveness against influenza A(H1N1) in the 2013–2014 season in the US came to light (4,5).

Figure 1 provides a visual summary of the milestones in the development of recommendations on the use of LAIV in Canada and the US. Table 1 provides a verbal summary of these events.

First trigger for potential NACI review of LAIV guidance

In October 2014, a few months after ACIP made its preferential recommendation, post-market monitoring studies found evidence of low to no LAIV effectiveness against influenza A(H1N1) in US children and adolescents 2–17 years old in the 2013–2014 season; this evidence was presented to ACIP (6).

Figure 1: Milestones of recommendations on LAIV use in Canada and the US

Abbreviations: ACIP, Advisory Committee on Immunization Practices; CDC, United States Centers for Disease Control and Prevention; IWG, Influenza Working Group; LAIV, live-attenuated influenza vaccine; NACI, National Advisory Committee on Immunization; SPSN, Sentinel Practitioner Surveillance Network; UK, United Kingdom; US, United States; VE, vaccine effectiveness

CCDR • May/June 2021 • Vol. 47 No. 5/6 • Page 280
The low LAIV performance observed in the US led NACI to initiate a rapid review of the evidence to determine whether there was a need to revise its recommendation on how LAIV should continue to be used in Canada. The evidence review needed to be rapid to inform provincial and territorial procurement decisions that would be made early in 2015 for the 2015–2016 influenza season. By November 2014, invited speakers from the US Centers for Disease Control and Prevention (CDC) and MedImmune, the manufacturer of LAIV, had presented their US LAIV effectiveness data to NACI and its Influenza Working Group (IWG). At the time, MedImmune proposed that the reduced effectiveness against influenza A(H1N1) seen in the US may have been due to the vulnerability to heat degradation of the A/California/7/2009(H1N1)pdm09-like strain present in the vaccine, which may have occurred during vaccine distribution. In December 2014, Canada’s Sentinel Practitioner Surveillance Network (SPSN) shared with NACI unpublished Canadian LAIV effectiveness data from the 2013–2014 season that showed that the effectiveness of LAIV was similar to IIV, which differed from the US data.

After reviewing this effectiveness data from the 2013–2014 season, NACI published an opinion statement in late January 2015, in time to inform provincial and territorial procurement decisions for the upcoming 2015–2016 season. The opinion statement indicated that no change would be made to NACI’s preferential recommendation on LAIV use (7). NACI’s decision also took into consideration factors other than vaccine effectiveness, including the different LAIV formulations used in the US (quadrivalent) and Canada (trivalent) in 2013–2014; differences in the temperature-controlled vaccine distribution between the two countries; and the fact that the low LAIV effectiveness seen in the US studies for the 2013–2014 season was not seen in Canadian post-market LAIV effectiveness data from SPSN for the same season (8). In contrast, in February 2015, ACIP reversed its preferential LAIV use recommendation to indicate either LAIV or IIV were appropriate vaccine options in children aged 2–8 years for the 2015–2016 season (9).

As a result of the manufacturer’s thermal stability investigations, the A(H1N1)pdm09 component of LAIV was changed for the 2014–2015 season from the A/California/7/2009 strain to the antigenically similar and more heat stable A/Bolivia/559/2013 strain. Whether the strain change for LAIV improved its performance for the 2014–2015 influenza season as compared to the inactivated vaccine was inconclusive as the season was dominated by antigenically drifted A(H3N2) viruses. Both LAIV and IIV performed poorly for the 2014–2015 season; a majority of studies found no evidence that either type of vaccine protected against any influenza and influenza A(H3N2) (10).

**Second trigger for potential NACI review of guidance**

Post-market monitoring studies completed in the US at the end of the 2015–2016 season again found low vaccine effectiveness for LAIV, but not IIV, against influenza A(H1N1) in children and adolescents aged 2–17 years (11). On June 22, 2016, ACIP recommended against the use of LAIV for the 2016–2017 season. ACIP’s decision was driven by the reduced effectiveness observed for LAIV against A(H1N1) in the US over the 2013–2014 and 2015–2016 seasons when predominately influenza A(H1N1)pdm09-like viruses circulated (12,13). This decision garnered widespread attention and generated a high degree of interest from Canadian stakeholders.

### Table 1: Timeline of NACI responses to the LAIV performance signals from the US

<table>
<thead>
<tr>
<th>Date</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>First signal</td>
<td>On October 29, 2014, evidence of low LAIV effectiveness for the 2013–2014 influenza season in the US was presented to ACIP.</td>
</tr>
<tr>
<td>November 18, 2014</td>
<td>LAIV effectiveness data from the US for the 2013–2014 season were presented to a joint meeting of NACI, NACI IWG and CIC (representing provincial and territorial immunization programs).</td>
</tr>
<tr>
<td>Late November to December 2014</td>
<td>Canada’s SPSN shared LAIV effectiveness data for the 2013–2014 season with NACI. Based on the available evidence, NACI concluded that no change will be made to the recommendation on LAIV use for the 2015–2016 season.</td>
</tr>
<tr>
<td>January 26, 2015</td>
<td>NACI’s position on LAIV in use in response to the first signal was distributed to provincial and territorial stakeholders.</td>
</tr>
<tr>
<td>July 4, 2016</td>
<td>PHAC hosted a teleconference with CIC to discuss the LAIV effectiveness signal from the US and NACI’s plans to review the available evidence. NACI’s secretariat at PHAC started synthesizing available post-2009 LAIV effectiveness data.</td>
</tr>
<tr>
<td>July 19, 2016</td>
<td>Post-2009 LAIV effectiveness data, including data from Canada, the US and other jurisdictions for the 2015–2016 influenza season, were presented to NACI’s IWG for deliberation. Based on the available evidence, the IWG proposed a recommendation change for NACI’s consideration.</td>
</tr>
<tr>
<td>July 26, 2016</td>
<td>NACI concluded that the available evidence did not support a recommendation for the preferential use of LAIV over IIV, but LAIV remained an influenza vaccine option for children.</td>
</tr>
<tr>
<td>July 29, 2016</td>
<td>NACI’s position on LAIV in use in response to the second signal was distributed to provincial and territorial stakeholders.</td>
</tr>
</tbody>
</table>

Abbreviations: ACIP, Advisory Committee on Immunization Practices; CIC, Canadian Immunization Committee; IIV, inactivated influenza vaccine; IWG, Influenza Working Group; LAIV, live-attenuated influenza vaccine; NACI, National Advisory Committee on Immunization; PHAC, Public Health Agency of Canada; SPSN, Sentinel Practitioner Surveillance Network; US, United States
The new US LAIV data and ACIP’s recommendation against the use of LAIV in the US raised concerns regarding the use of LAIV in Canada from provincial and territorial immunization programs, which had already procured LAIV. All of these factors were triggers for NACI to once again review its guidance on LAIV use in Canada.

NACI’s challenge in response to this trigger was the time constraint to provide a very rapid evidence-informed decision on the use of the already procured LAIV mere months from the start of provincial and territorial immunization campaigns (typically October) for the upcoming season. On July 4, 2016, PHAC held a meeting with stakeholders from provincial and territorial immunization programs to brief them about the new LAIV effectiveness data from the US and to inform them of NACI’s planned activities to review additional Canadian and international effectiveness data for LAIV to inform NACI’s review of its LAIV recommendations.

On July 19, 2016, the NACI IWG reviewed unpublished post-market monitoring data from six sources: Canada’s SPSN; the US Influenza Vaccine Effectiveness Network (US Flu VE Network); the US Department of Defense; the United Kingdom’s influenza vaccine effectiveness network; the National Institute for Health and Welfare of Finland; and MedImmune. The IWG also reviewed and unpublished post-2009 pandemic data to assess the trend of LAIV effectiveness over the influenza seasons since the A(H1N1)pdm09 pandemic strain displaced the pre-pandemic influenza A(H1N1) strains. These included findings from two Canadian cluster randomized controlled trials that did not find reduced LAIV effectiveness for the 2013–2014 season in Canada (14,15), which aligned with findings from SPSN for that season.

Following reviews of the available evidence, which showed LAIV providing protection against influenza comparable to that afforded by IIV, and discussions with various jurisdictions, the IWG recommended that NACI change its recommendations on the use of LAIV. On July 26, 2016, based on the advice from the IWG and after considering all the available evidence, NACI concluded that the available evidence no longer supported a recommendation for the preferential use of LAIV over IIV, but that LAIV remained an option for the annual influenza vaccination of children aged 2–17 years (6). Although the US data showing LAIV effectiveness to be comparable or lower than IIV effectiveness contributed to NACI’s revised, non-preferential recommendation on LAIV use, the reduced effectiveness seen in the US for the 2015–2016 season was again not observed in Canada or other countries that investigated the issue (10). The difference in LAIV performance data from Canada and other international jurisdictions compared to data from the US played an important role in informing NACI’s decision to continue to recommend LAIV use in Canada for the 2016–2017 season (16).

NACI’s official position was communicated to stakeholders in late July 2016 (6,10,16). The effectiveness data supporting NACI’s decision has been detailed elsewhere (10).

Epilogue

The poor performance of the A(H1N1) component of LAIV in the 2015–2016 influenza season was attributed to reduced replicative fitness of the vaccine A(H1N1)pdm09-like strain. Similar to the 2013–2014 season, differences in the temperature-controlled vaccine distribution between Canada and the US could be a factor in the differential performance of LAIV in the two countries for the 2015–2016 season. Due to the finding of reduced replicative fitness, the A(H1N1)pdm09-like strain in the 2015–2016 vaccine formulation (A/Bolivia/559/2013) was replaced with a new strain (A/Slovenia/2903/2015) for the 2017–2018 season (13).

ACIP maintained their recommendation against LAIV use for the 2017–2018 season. However, in February 2018, ACIP voted to reinstate LAIV as a vaccine option for the 2018–2019 season, with no preference given to LAIV or IIV for the paediatric age group, based on data provided from the manufacturer suggesting that the new A(H1N1)pdm09-like strain (A/Slovenia/2903/2015) has improved replicative fitness over previous A(H1N1)pdm09-like vaccine strains in LAIV (12). This non-preferential recommendation is maintained by ACIP in their latest statement for the 2020–2021 season (17). NACI’s recommendation for the non-preferential use of LAIV in children and adolescents aged 2–17 years remains unchanged going into the 2021–2022 influenza season (18).

Discussion

NACI and ACIP arrived at different conclusions on the use of LAIV in response to the post-market LAIV performance signals from the US for the 2013–2014 and 2015–2016 seasons, but differing recommendations by NITAGs are not unusual. NITAGs consider a multitude of factors when making their recommendations, including vaccine characteristics (efficacy, effectiveness, immunogenicity and safety), local burden of disease, and vaccine effectiveness data. Based on this complex multifactorial analysis and differential weighting of these factors in their analyses, it is not surprising that NITAGs often arrive at different conclusions about which immunization strategy will best address the needs of their specific country.

NACI’s rapid evidence appraisal and decision-making in response to the low LAIV effectiveness data from the US was facilitated by several critical factors. Being able to depend on seasonal influenza vaccine effectiveness assessments from established Canadian influenza surveillance networks was one facilitator. Canada’s SPSN provided a near real-time assessment of their data to NACI and PHAC to inform NACI’s deliberations on LAIV use in children.

Another facilitator was having Canadian influenza vaccine effectiveness data from studies that were specifically designed and appropriately powered to compare LAIV and IIV, such as
the cluster randomized clinical trials that corroborated the SPSN surveillance findings from the 2013–2014 season. (SPSN was not designed to compare the effectiveness of specific vaccine products.)

A third facilitator was collaboration with international and industry partners. Sharing of intelligence on emerging signals and unpublished data was pivotal to informing NACI’s guidance development with the best available evidence in these time-sensitive situations. There were also several critical factors that contributed to successfully meeting the evidence-to-guidance challenge from an operational perspective. These included having established processes to facilitate stakeholder engagement and mobilizing surge capacity within PHAC to provide technical and logistical support to NACI.

Conclusion
NACI’s response to the post-market LAIV performance signals from the US represents an example of its capacity to respond rapidly and comprehensively to the dynamic landscape of international vaccine research and infectious disease epidemiology. These responses highlight the importance of establishing and leveraging existing channels for intelligence sharing and knowledge exchange with evidence producers, partners and users and the importance of considering evidence from multiple sources and the local context for informing decision-making. NACI’s experience with and capacity for timely responses to post-market vaccine performance signals will facilitate responsiveness to similar post-market monitoring signals from the coronavirus disease 2019 (COVID-19) vaccines.

Authors’ statement
LZ — Conceptualization, writing—original draft, writing—review and editing
KY — Conceptualization, writing—review and editing
AH — Conceptualization, writing—review and editing
RS — Conceptualization, writing—review and editing
MT — Conceptualization, writing—review and editing

Competing interests
None.

Funding
This work was supported by the Public Health Agency of Canada.

References


